Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ERIC CLL 2026 | Potential of BCR-directed CAR T-cell therapy across malignancies and autoimmune disorders

Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, discusses the potential of B-cell receptor (BCR)-directed CAR T-cells to target specific pathogenic B-cell populations across various malignancies and autoimmune disorders. Dr Ruella notes that this approach could offer more targeted therapy, reduce toxicity, and potentially benefit patients with autoimmune diseases. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.